Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BTK
REST API REST API
Homo sapiens
BTK is differentially expressed in 199 experiments: 80 organism parts: lung, bone marrow, ... (78 more);, 207 disease states: normal, lung adenocarcinoma, ... (205 more);, 85 cell types 329 cell lines 19 compound treatments and 64 other conditions.
Synonyms PSCTK1, IMD1, AGMX1, XLA, ATK
Orthologs D3ZHD2_RAT (Rattus norvegicus)   btk (Danio rerio)   Btk (Mus musculus)   Q5ZLF2_CHICK (Gallus gallus)   Q3ZC95_BOVIN (Bos taurus)   btk (Xenopus laevis)   BTK (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, protein binding, cytoplasm, innate immune response, peptidyl-tyrosine phosphorylation, metal ion binding, protein tyrosine kinase activity, membrane raft, I-kappaB kinase/NF-kappaB cascade, identical protein binding, ATP binding, nucleus, mesoderm development, nucleotide binding, kinase activity, protein serine/threonine kinase activity, cytoplasmic vesicle, positive regulation of NF-kappaB transcription factor activity, calcium-mediated signaling, non-membrane spanning protein tyrosine kinase activity, protein kinase activity, positive regulation of B cell differentiation, phosphatidylinositol-3,4,5-trisphosphate binding, B cell receptor signaling pathway, B cell activation, cell maturation, induction of apoptosis by extracellular signals, adaptive immune response, regulation of B cell apoptosis, protein phosphorylation, intracellular signal transduction, regulation of B cell cytokine production
InterPro Term SH2, SH3_domain, Znf_Btk_motif, Prot_kinase_cat_dom, Pleckstrin_homology, SH3_2, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q5JY90, Q3MS88, Q3MS90, Q06187, Q3MS94, Q3MS95, Q3MS96, Q572P5, Q9P0L4
Gene-Disease Assocation AGAMMAGLOBULINEMIA, X-LINKED; XLA, ISOLATED GROWTH HORMONE DEFICIENCY, TYPE III; IGHD3
Search EB-eye ENSG00000010671
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-1880, E-MEXP-1006, E-GEOD-19639, ... (20 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MCF-7
1
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
SW480
2
E-MEXP-1014, E-MTAB-37
AsPC1
1
E-MTAB-37
NA18501
1
E-GEOD-19480
Wi38
1
E-MTAB-37
323 more value(s).


Cell type

studied in E-GEOD-21668, E-MEXP-120, E-MEXP-66, E-GEOD-20677, E-GEOD-13987, ... (38 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
whole blood
2
E-GEOD-3026, E-MTAB-25
79 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-25, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, ... (45 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MEXP-231, E-MTAB-62, E-GEOD-2514
gastric carcinoma
3
E-GEOD-15460, E-MTAB-37, E-GEOD-2685
acute promyelocytic leukemia
3
E-MTAB-62, E-GEOD-96, E-GEOD-995
chronic lymphocytic leukemia
3
E-MTAB-37, E-GEOD-2466, E-GEOD-6691
glioblastoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-4290
prostate carcinoma
3
E-GEOD-96, E-MTAB-62, E-MTAB-37
201 more value(s).


Compound treatment

studied in E-GEOD-7400, E-TABM-782, E-GEOD-5824, E-TABM-868, E-GEOD-5099, ... (17 experiments)

Factor Value U/D Experiments
none
4
8
E-GEOD-2649, E-MEXP-1601, E-TABM-868, E-MEXP-1230, E-GEOD-2803, ... (12 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
PGE2
1
E-MEXP-1230
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
interferon-gamma + lipopolysaccharide
1
1
E-GEOD-5099, E-GEOD-7307
13 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19665

double amplification
studied in E-GEOD-22601

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-GEOD-17385

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-TABM-321, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-1446, E-GEOD-22278, E-MEXP-1103, E-MEXP-2146 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-3606, E-TABM-118, ... (27 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-17400

Injury
studied in E-GEOD-19743

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-19703, E-GEOD-21750

Population
studied in E-MTAB-197, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-101

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-19069, E-GEOD-2466

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.256 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM